Melatonin treatment improves primary progressive multiple sclerosis: a case report

被引:48
|
作者
Lopez-Gonzalez, Antonio [1 ,2 ]
Alvarez-Sanchez, Nuria [3 ]
Lardone, Patricia J. [3 ,4 ]
Cruz-Chamorro, Ivan [3 ,4 ]
Martinez-Lopez, Alicia [3 ]
Guerrero, Juan M. [3 ,4 ,5 ]
Reiter, Russel J. [6 ]
Carrillo-Vico, Antonio [3 ,4 ]
机构
[1] Virgen Macarena Univ Hosp, Dept Neurosurg, Seville, Spain
[2] Virgen del Rocio Univ Hosp, Dept Neurosurg, Seville, Spain
[3] Univ Seville, CSIC, Virgen del Rocio Univ Hosp, Inst Biomed Seville IBiS, Seville 41013, Spain
[4] Univ Seville, Sch Med, Dept Med Biochem Mol Biol & Immunol, Seville 41013, Spain
[5] Virgen del Rocio Univ Hosp, Dept Clin Biochem, Seville, Spain
[6] UT Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX USA
关键词
melatonin; multiple sclerosis; primary progressive multiple sclerosis; OXIDATIVE DAMAGE; NATURAL-HISTORY; NERVOUS-SYSTEM; EXPRESSION; ANTIOXIDANT; PREVALENCE; CELLS; GENETICS; ETIOLOGY; STRESS;
D O I
10.1111/jpi.12203
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We describe the case of a female patient who, at the age of 28, was diagnosed with symptoms of primary progressive multiple sclerosis (PPMS). Glucocorticoid treatment was immediately initiated. The disease and the demyelinating lesions progressed during the following 9 years reaching Expanded Disability Status Scale (EDSS) 8.0 (patient essentially restricted to bed, a chair or perambulated in a wheelchair). At this point, the patient began taking melatonin at doses ranging from 50 to 300 mg per day. Melatonin was her only treatment for the next 4 years; during this interval, her EDSS progressively recovered to 6.0 (the person needs intermittent or unilateral constant assistance such as cane, crutch, or brace to walk 100 meters with or without resting). This long-lasting improvement is likely due to melatonin usage since it is related in time and because of its exceptionally long duration.
引用
收藏
页码:173 / 177
页数:5
相关论文
共 50 条
  • [31] Ocrelizumab for primary progressive multiple sclerosis
    Adler, Ai
    Knight, H.
    LANCET NEUROLOGY, 2019, 18 (09): : 816 - 817
  • [32] NEUROPSYCHOLOGY OF PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
    Paes, R. A.
    Alvarenga, R. M. P.
    Vasconcelos, C. C. F.
    Negreiros, M. A.
    Landeira-Fernandez, J.
    REVISTA DE NEUROLOGIA, 2009, 49 (07) : 343 - 348
  • [33] Neuropsychology of primary progressive multiple sclerosis
    Paes, R.
    Papais-Alvarenga, R.
    Vasconcelos, C.
    Negreiros, M. A.
    Landeira, J.
    JOURNAL OF NEUROLOGY, 2008, 255 : 82 - 82
  • [34] Ocrelizumab for primary progressive multiple sclerosis
    Montalban X
    Hauser SL
    Kappos L
    中华物理医学与康复杂志, 2017, (03) : 174 - 174
  • [35] The pathology of primary progressive multiple sclerosis
    Lucchinetti, C
    Bruck, W
    MULTIPLE SCLEROSIS JOURNAL, 2004, 10 : S23 - S30
  • [36] Primary progressive multiple sclerosis in Brazil
    Vasconcelos, CCF
    Alvarenga, M
    Papais-Alvarenga, R
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 238 : S218 - S219
  • [37] Primary and secondary progressive multiple sclerosis
    Vukusic, S
    Confavreux, C
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2003, 206 (02) : 153 - 155
  • [38] The pathology of primary progressive multiple sclerosis
    Brück, W
    Lucchinetti, C
    Lassmann, H
    MULTIPLE SCLEROSIS, 2002, 8 (02): : 93 - 97
  • [39] The diagnosis of primary progressive multiple sclerosis
    Wolinsky, JS
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2003, 206 (02) : 145 - 152
  • [40] Primary-progressive multiple sclerosis
    Miller, David H.
    Leary, Siobhan M.
    LANCET NEUROLOGY, 2007, 6 (10): : 903 - 912